Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Research Reports

Gastrointestinal Stromal Tumor Market Global Leading Companies Analysis, Revenue, Trends and Forecasts 2027

Published On :

 

 

The Gastrointestinal Stromal Tumor Market is all set to be in the driver’s seat shortly. Technology adoption once looked upon as a costly endeavor, is slated to witness a drastic transformation in the form of granular applications. Technologies like DevOps and AIOps are constructively disrupting the healthcare IT sector and are expected to create wonders in this regard in the upcoming period.

The Gastrointestinal Stromal Tumor Market is expected to be worth US$ 1.5 Billion at a CAGR of 6.6% between 2026. Healthcare is going the “digital” way. In other words, artificial intelligence (AI)-enabled medical devices and telemedicine are the concrete instances of the proliferation of the digital wave in the healthcare industry. This factor would be the one traversing the healthcare vertical in the forecast period.

Persistence Market Research’s exclusive forecast study on the global market for gastrointestinal stromal tumor (GIST) estimates that the treatments for such malignant cancer will bring in more than US$ 1.5 Bn revenues, globally, by the end of 2026.

The study has addressed a range of factors influencing the growth of the global gastrointestinal stromal tumor market for the assessment period, 2017-2026. From genetic changes to bad dietary lifestyles and increasing presence of adulterants in common foods, several factors are expected to fuel the demand for treatments on GISTs.

How About Looking Through The Sample Of Gastrointestinal Stromal Tumor Market Report? https://www.persistencemarketresearch.co/samples/20626

Company Profiles

  • Novartis AG
  • Sun Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Bayer Aktiengesellschaft
  • NATCO Pharma Limited

Get A Customized Scope To Match Your Need Ask An Expert –  sales@persistencemarketresearch.com

While most of the drivers for the global gastrointestinal stromal tumor market are indicative of driving the incidence of this tumor, some factors are expected to represent patient attitudes and pharmaceutical outcomes.

During the forecast period, the global gastrointestinal stromal tumor market is estimated to expand robustly at a CAGR of 6.6%. Increasing developments in the research on new drug candidates for controlling the outgrowth of gastrointestinal stromal tumor cells will be factoring the market’s growth to a considerable extent. Notwithstanding as one of the most common forms of cancer, the incidence rate of GIST continues to be remarkably low.

The World Health Organization states that in the US, the estimated incidence rate of gastrointestinal stromal tumor is 14.5 per million. The study projects that through 2026, North America will be observed as the largest market for gastrointestinal stromal tumor.

Increasing presence of genetic disorders in the US, robust healthcare infrastructure, availability of exclusive medical facilitates for caretaking of patients suffering from inoperable cancers will continue to drive the growth of North America’s gastrointestinal stromal tumor market through 2026.

Over the forecast period, the gastrointestinal stromal tumor market in North America is anticipated to register a 6.9% CAGR style=”font-weight: 400;”>, recording highest revenues. The study also estimates that Europe will be at the forefront of the global gastrointestinal stromal tumor market expansion during the forecast period.

Want To Keep A Tab On The Latest Findings In The Gastrointestinal Stromal Tumor Market? Purchase Our Gastrointestinal Stromal Tumor Market Report Now! https://www.persistencemarketresearch.com/checkout/20626

Patients to Opt for Conventional Symptomatic Treatments such as Chemotherapy

Being inoperable in nature, gastrointestinal stromal tumor has a limited treatment scope. The role of radiotherapy in gastrointestinal stromal tumor treatment remains unestablished till date. Patients seek symptomatic treatments such as chemotherapy while medical professionals await a clinical practice breakthrough.

In 2017, more than US$ 185 Mn worth of revenues were procured globally from treatment of gastrointestinal stromal tumor with chemotherapy. The study also projects that targeted drug therapy will gain traction as a viable treatment for early-stage GISTs in the foreseeable future.

Difficulties in Clearing FDA Pipeline

Currently, the competition landscape in the global gastrointestinal stromal tumor market exhibits the presence of only a handful of players. Companies namely, Sun Pharmaceutical Industries Limited, Novartis AG, Pfizer Inc., NATCO Pharma Limited, and Bayer Aktiengesellschaft are expected to remain active in expansion of the global GIST market from 2017 to 2026.

Several leading pharma companies are anticipated to penetrate the consolidated competition in the global market during the forecast period. Unable to clear the FDA approvals remains the key impediment and entry barrier in the global gastrointestinal stromal tumor market.

High End-use in Hospitals; Stomach Indication to Account for Nearly 3/5th Share of Global Revenues

Additional research findings from the report reveal that stomach is the key segment in terms of indication of GISTs. While the occurrence of gastrointestinal stromal tumor may take place in any part of the GI tract, its localization remains common in the stomach.

In 2017, stomach as an indication will account for nearly US$ 500 Mn revenues in the global market. The report also expects that hospitals will be the largest end-users in the global market, and will rake in over US$ 485 Mn revenues from treatments of GISTs by 2026-end.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com

 

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts